Clinical trial
Dose-response Study of OPC-12759 Ophthalmic Suspension
NCT00234078 · Otsuka Pharmaceutical Co., Ltd., Industry · Completed
Key facts
| NCT number | NCT00234078 |
|---|---|
| Title | Dose-response Study of OPC-12759 Ophthalmic Suspension |
| Official title | Dose-response Study of OPC-12759 Ophthalmic Suspension |
| Lead sponsor | Otsuka Pharmaceutical Co., Ltd., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Dry Eye Syndromes |
| Intervention type | Drug |
| Interventions | 0.5% OPC-12759, 1% OPC-12759, 2% OPC-12759, placebo |
| Enrollment | 290 |
| Start date | Jan 1, 2005 |
| Primary completion | Apr 1, 2006 |
| Completion | Mar 1, 2007 |
| First posted | Oct 6, 2005 |
| Last update posted | Feb 28, 2014 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: